Break the pain cycle—relax, sleep and recover

September 7, 2018, CORDIS
Break the pain cycle—relax, sleep and recover
Credit: Sana

Extreme pain is highly destructive, often accompanied by fatigue, sleep disturbance, decreased appetite and mood changes. A novel nerve activity modulator technology addresses the pain and welcome sleep follows.

A motor accident left Richard Hanbury, founder and CEO of Sana Health UK Ltd, a paraplegic in excruciating . Doctors gave him five years to live due to from chronic nerve damage. In collaboration with experts in pain, and flow states, Hanbury started to research flow state technology and develop a smart eye mask to reduce pain and improve healing. Today, some 17 years later, he uses a wheelchair and continues the work – with the help of EU funding under the project Sana.

One device—A host of applications

"Sana is a neuromodulation device that uses audio visual stimulation and a heart rate variability (HRV) feedback loop customisable for the individual," Hanbury explains. The mask triggers an increase in neuroplasticity lending itself to applications in areas of mental health through impacted sleep and relaxation levels including sleep disorders, pain management, post-traumatic stress disorder (PTSD), concussion and stroke.

The device uses a complex and proprietary pattern of light and sound with a closed loop biofeedback system that balances activity in the two brain hemispheres inducing a flow state. Increasing relaxation, the flow state reduces pain and then may trigger sleep in an average of 10 minutes.

Least invasive pain reliever, use anywhere, anytime

Advantages of the Sana eye mask are that it is fast-acting, personalised and comfortable with no negative side effects. Long term positive results are that it works cumulatively to normalise nerve pathways and there is no prescription needed.

Alternatives to induce this state include the use of opioids. Problems with the use of these drugs include addiction, side effects such as extreme constipation and the threat of overdose. Implantable pain relief devices are prohibitively expensive and sometimes ineffective.

Convincing results from trials

The Sana project has just completed a study at the Stanford School of Medicine. With 75 subjects, the trial measured subjective changes in relaxation and pain and objective variations in heart rate. Overall, the participants had a doubling of relaxation, a threefold reduction in pain levels and recovery and sleep was improved fivefold.

This was a controlled test to look at subjective levels of relaxation and pain reduction, and objective measures of HRV (HFn) changes, measuring the spectrum of power density. Hanbury explains, "We chose HRV (HFn) as our chief metric, because this has been correlated with sleep latency, and sleep quality – essentially the more relaxed you are the higher your HRV (HFn), the faster you go to sleep and the better the quality of your sleep."

In November at Mount Sinai Hospital, a trial will look at 120 subjects (60 using the device and 60 with a sham) with diabetes, stroke or traumatic brain injury, this is designed to be a pivotal FDA study for Sana.

Ready and waiting for Sana with financial backing

Sana is getting ready for an Over-The-Counter market launch after obtaining Food and Drug Administration (FDA) approval. They have raised over USD 3 million this round. Founders Fund leading, and commitments from HealthTech Capital and three industry angels.

Organisations waiting in the wings to collaborate on sleep, pain and PTSD include 20 sports teams, 8 hospitals and 6 military groups. The mask device has won various awards – Under Armour Innovation Sports Tank Award, the Bayer Global Challenge Winner for collaboration and the winner of the Mount Sinai and the Massachusetts Institute of Technology (MIT) Rehab Medicine Challenge.

The team believes Sana is a powerful tool for . Route-to-market is the pivotal FDA trial with Mount Sinai and MIT, then pain clinic and hospital sales. "Sleep and constitute a challenge that no one else is currently trying to solve. The opioid crisis is currently acting to highlight the need for non-drug options in this area," Hanbury concludes.

Explore further: Poor sleep worsens link between PTSD, chronic pain in youth

Related Stories

Poor sleep worsens link between PTSD, chronic pain in youth

February 4, 2018
(HealthDay)—Poor sleep worsens the association between posttraumatic stress disorder (PTSD) symptoms and chronic pain in youth, according to a study published in the January issue of the Journal of Pain.

Study finds no link between sleep apnea and joint pain

August 1, 2016
Consistent with previous reports, poor sleep quality was linked with joint pain in a recent Arthritis Care & Research study of the general population, but the study found no association between obstructive sleep apnea and ...

Fatigue not a factor in fibromyalgia pain, study says

April 26, 2012
(HealthDay) -- Poor sleep is not a significant predictor of pain intensity and duration in patients with fibromyalgia, a new study says.

Pediatric ward noise at night exceeds recommended levels

August 1, 2018
(HealthDay)—Children and their mothers have poorer quality sleep in pediatric hospital wards than they do at home, and this may be due to significantly raised sound levels in the hospital, according to a study published ...

Sleep is key to curing chronic pain

September 21, 2016
Research from the University of Warwick reveals that the way chronic pain patients think about pain and sleep leads to insomnia and poor management of pain.

To treat pain, look at more than the 1-10 scale

May 4, 2018
People in chronic pain are some of the most difficult patients to treat. They have complex circumstances that medicine can't always remedy. Pain can be amplified, by depression and anxiety, genetics and quality of life. Genetics ...

Recommended for you

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.